VirTech Bio
VirTech Bio is an early-stage biotechnology company based in Natick, Massachusetts, focused on developing a human-derived hemoglobin-based oxygen carrier (HBOC) for use as a temporary blood substitute in trauma and transplantation. The company leverages expertise in hemoglobin polymerization to address critical needs in emergency medicine and organ preservation, with a pipeline also targeting veterinary and research applications. Process innovations allow scalable and contract-based manufacturing, supported by significant non-dilutive funding from the US Department of Defense and private investment.
Patents
Blood substitutes comprising hemoglobin and methods of making
2022-11-22 • US-11504417-B2
View DetailsWhat We Do
Concentrated human-derived hemoglobin solution, ultra-polymerized for prolonged circulation and tissue oxygenation, targeting hemorrhagic shock and trauma.
Oxygen-carrying hemoglobin solution for use in organ perfusion devices to improve viability and survival of transplant organs.
Development-stage blood substitute for animal use, designed to support veterinary surgery and field anesthesia needs.
Stable hemoglobin solution for use as an oxygen transport reagent in laboratory research, biofabrication, and organoid culture.
Regenerative Medicine
Digital Health Technologies
Key People
News & Updates
Secured significant non-dilutive funding to support R&D, manufacturing, and clinical studies for hemoglobin-based oxygen carriers.
US Patent 11,504,417 issued, covering blood substitutes comprising hemoglobin and related manufacturing methods.
Funding and development milestones for hemoglobin-based oxygen carrier technology to address trauma and transplantation needs.
Expansion of advisory board with leaders in hematology, anesthesiology, and medical device industry.
Operational and scientific milestones, including process development, preclinical results, and funding for hemoglobin-based oxygen carrier advancement.
Presentation on company progress, novel hemoglobin-based oxygen carrier development, and plans for clinical advancement.